LENZ Therapeutics (Nasdaq: LENZ), focused on commercializing VIZZ (aceclidine ophthalmologic solution) 1.44% for presbyopia in adults, will participate in three upcoming investor conferences. Management will host 1x1 investor meetings in Chicago on June 2, New York on June 3, and Miami on June 9, 2026.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – LENZ
+2.65%
1 alert
+2.65%Session close to close
+3.0%Peak Tracked
$254.60MMarket Cap
0.1xRel. Volume
In the May 26 session, LENZ gained 2.65%, reflecting a moderate positive market reaction.
Argus tracked a peak move of +3.0% during that session.
SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences:
William Blair 46th Annual Growth Stock Conference Date: June 2, 2026 Location: Chicago, IL Format: 1x1 investor meetings
2026 Jefferies Global Healthcare Conference Date: June 3, 2026 Location: New York, NY Format: 1x1 investor meetings
Goldman Sachs 47th Annual Global Healthcare Conference Date: June 9, 2026 Location: Miami, FL Format: 1x1 investor meetings
About LENZ Therapeutics LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit www.VIZZ.com and www.LENZ-tx.com.
Contacts: Dan Chevallard LENZ Therapeutics IR@LENZ-Tx.com
FAQ
Which investor conferences will LENZ Therapeutics (NASDAQ: LENZ) attend in June 2026?
LENZ Therapeutics will attend the William Blair Growth Stock Conference, Jefferies Global Healthcare Conference, and Goldman Sachs Global Healthcare Conference in June 2026. According to the company, management will hold 1x1 investor meetings at all three events across Chicago, New York, and Miami.
When and where is LENZ Therapeutics presenting at the William Blair 46th Annual Growth Stock Conference?
LENZ Therapeutics will participate in the William Blair 46th Annual Growth Stock Conference on June 2, 2026, in Chicago, Illinois. According to LENZ, the company will conduct 1x1 investor meetings at this event rather than a formal public presentation session.
What is the schedule for LENZ Therapeutics at the 2026 Jefferies Global Healthcare Conference?
LENZ Therapeutics will take part in the 2026 Jefferies Global Healthcare Conference on June 3, 2026, in New York, New York. According to the company, its management team will be available for 1x1 investor meetings during the conference to discuss its business.
How will LENZ Therapeutics engage investors at the Goldman Sachs 47th Annual Global Healthcare Conference?
LENZ Therapeutics plans to attend the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, in Miami, Florida. According to the company, management will host 1x1 investor meetings, offering institutional investors direct access to discuss its strategy and product portfolio.
What does LENZ Therapeutics focus on and what is VIZZ eye drop?
LENZ Therapeutics focuses on commercializing VIZZ, an aceclidine ophthalmologic solution 1.44% for adult presbyopia. According to the company, VIZZ is the first and only FDA-approved aceclidine-based eye drop treatment for presbyopia, supporting its positioning in the ophthalmology market.
